Citations

Clear

499 citation(s) found for "Tracy, PB".

Intravesical rad-IFNα/Syn3 for patients with high-grade, bacillus Calmette-Guérin (BCG) refractory or relapsed non-muscle invasive bladder cancer: A phase II randomized study.
Boorjian, Stephen A. , Canter, Daniel , Ogan, Kenneth , Downs, Tracy , Gomella, Leonard G. , Svatek, Robert S. , Bivalacqua, Trinity J. , Grubb, Robert L. , Krupski, Tracey L. , Woods, Michael, Inman, Brant A. , Milowsky, Matthew I. , Parker, Nigel, Sawutz, David G., Shore, Neal D. , Karsh, Lawrence Ivan , Kamat, Ashish M. , Lotan, Yair , Lerner, Seth P. , Dinney, Colin P. , Inman, Brant A

Mayo Clinic

Journal of Clinical Oncology | March 29, 2017 | Volume: 35 | Issue: 6_suppl | Pages: 279-279

10.1200/jco.2017.35.6_suppl.279 Get It

279 Background: While bacillus Calmette-Guérin (BCG) is the most effective intravesical treatment for reducing recurrence and progression for high-risk non-muscle invasive bladder cancer (NMIBC), many patients are either refractory to treatment or relapse. We assessed the efficacy and safety of rAd-IFNα/Syn 3 (Instiladrin, FKD Finland), a replication deficient recombinant adenovirus gene transfer vector, for patients with high-grade (HG) BCG refractory or relapsed NMIBC. Methods: In this open-label, US multicenter (n=13), parallel-arm Phase II study (NCT01687244), 43 patients with HG BCG refractory or relapsed NMIBC were randomized 1:1 to receive intravesical rAd-IFNα/Syn3 at 1x1011 or 3x1011viral particles/mL. Patients responding at months 3, 6, and 9 were re-treated at months 4, 7, and 10. Most patients (n=21) had a primary tumor classification of carcinoma in situ (CIS); 9 had both CIS and Ta/T1 disease and 10 had Ta/T1 disease alone. The primary endpoint was 12-month HG recurrence-free survival (RFS). All patients receiving at least one dose were included in efficacy and safety analyses. Results: Forty patients received rAd-IFNα/Syn3 (1 x 1011 vp/mL: n=21; 3 x 1011vp/mL: n=19) between November 2012 and April 2015. Fourteen patients (35.0%; 90% CI 22.6%, 49.2%) remained free of HG tumor recurrence 12 months after initial treatment. Comparable 12 month HG RFS was noted between dosage arms, as well as between patients with refractory and relapsed NMIBC. Interestingly, the 12 month HG recurrence-free survival for patients with Ta/T1-only disease was 50% (5/10). rAd-IFNα/Syn3 was well-tolerated, with no Grade 5 adverse events (AEs), one Grade 4 AE (COPD; unrelated to treatment), and no patient discontinuing treatment due to an adverse event. The most frequently reported AEs were micturition urgency (n=16), dysuria and pollakiuria (n=13 each), fatigue (n=9), and nocturia (n=10). Conclusions: rAd-IFNα/Syn3 was well tolerated and demonstrated promising efficacy for patients with HG NMIBC after BCG therapy who are unable or unwilling to undergo radical cystectomy. A phase III trial utilizing this novel agent is ongoing. Clinical trial information: 01687244.
Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases
Haycock, Philip , Burgess, Stephen , Nounu, Aayah , Zheng, Jie , Okoli, George N. , Wade, Kaitlin H. , Timpson, Nicholas J. , Evans, David M. , Willeit, Peter , Aviv, Abraham , Gaunt, Tom R. , Hemani, Gibran , Mangino, Massimo , Ellis, Hayley, Kurian, Kathreena M. , Pooley, Karen A. , Eeles, Rosalind A. , Lee, Jeffrey E. , Fang, Shenying , Chen, Wei V., Law, Matthew H. , Bowdler, Lisa, Iles, Mark M. , Worrall, Bradford B. , Markus, Hugh S. , Hung, Rayjean J., Amos, Chris, Thompson, Deborah J. , O’Mara, Tracy A. , Wolpin, Brian M. , Ámundadóttir, Laufey T. , Trichopoulou, Antonia , Onland‐Moret, N. Charlotte , Lund, Eiliv , Canzian, Federico , Severi, Gianluca , Overvad, Kim , Gunter, Marc J. , ­Tumino, ­Rosario , Svenson, Ulrika, Rij, André van, Baas, Annette F., Bown, Matthew J. , Samani, Nilesh J. , t’Hof, Femke N.G. van, Tromp, Gerard , Jones, Gregory T. , Kuivaniemi, Helena , Elmore, James R. , Johansson, Mattias , McKay, James , Scélo, Ghislaine , Carreras‐Torres, Robert , Gaborieau, Valérie , Brennan, Paul , Bracci, Paige M. , Olson, Sara H. , Gallinger, Steven , Li, Donghui , Petersen, Gloria M. , Han, Jiali , Abnet, Christian C. , Freedman, Neal D. , Aben, Katja K.H. , Kiemeney, Lambertus A. , Vermeulen, Sita H. , Walsh, Kyle M. , Wrensch, Margaret , Rice, Terri, Turnbull, Clare , Litchfield, Kevin , Paternoster, Lavinia , Standl, Marie , Mijatovic, Vladan, Sapkota, Yadav , Zondervan, Krina T. , Nyholt, Dale R. , Heel, David A. van , Arking, Dan E. , Ashar, Foram N., Sotoodehnia, Nona, Woo, Daniel , Comeau, Mary E. , Brown, W. Mark , Silverman, Edwin K. , Hokanson, John E. , Hui, Jennie , Thompson, Philip J. , Morrison, Alanna C. , Smith, Nicholas L. , Christiano, Angela M. , Petukhova, Lynn , Betz, Regina C. , Zhang, Xuejun, Zhu, Caihong, Langefeld, Carl D. , Thompson, Susan D. , Wang, Feijie , Fingerlin, Tasha E. , Rotter, Jerome I. , Cotch, Mary Frances , Jensen, Richard A., Munz, Matthias , Dommisch, Henrik , Schäefer, Arne S. , Ollila, Hanna M. , Hillary, Ryan P. , Zeng, Chenjie , Zheng, Wei , Shu, Xiao-Ou , Reis, André , Uebe, Steffen , Hüffmeier, Ulrike , Kawamura, Yoshiya, Otowa, Takeshi , Sasaki, Tsukasa, Dávila, Sonia , Siminovitch, Katherine A. , Bei, Jin‐Xin , Zeng, Yi‐Xin , Chen, Bowang , Franke, Andre, Fischer, Annegret, Ellinghaus, David , Flores, Carlos , Noth, Imre , Ma, Shwu‐Fan , Foo, Jia Nee , Liu, Jianjun , Cox, David G. , Delattre, Olivier , Mirabeau, Olivier , Skibola, Christine F., Tang, Clara Sze-Man , Garcia-Barceló, Mercè, Su, Wen-Hui , Chang, Yu‐Sun , Wade, Tracey , Lee, Chaeyoung , Kubo, Michiaki , Cha, Pei-Chieng , Nakamura, Yusuke, Levy, Daniel , Hunt, S. E., Spector, Tim D. , Soranzo, Nicole , Barr, R. Graham, Kahali, Bratati , Speliotes, Elizabeth K. , Yerges-Armstrong, Laura M. , Cheng, Ching‐Yu , Wong, Tien Yin , Fogh, Isabella , Powell, John , Rice, Kenneth , Relton, Caroline L. , Martin, Richard M. , Smith, George Davey , Hung, Rayjean J. , Bowden, Jack , Yang, Qiong , Spurdle, Amanda B. , Stolzenberg‐Solomon, Rachael Z. , Duell, Eric J. , Neale, Rachel Ε. , Risch, Harvey A. , Klein, Alison P. , Taylor, Philip R. , Maris, John M. , Wiencke, John K. , Abecasis, Gonçalo R. , SanGiovanni, John Paul , Li, Yong , Low, Siew‐Kee , Montgomery, Grant W. , Hunt, Karen A. , Rosand, Jonathan M. , Cho, Michael H. , Ferreira, Manuel A. R. , Felix, Janine F. , Fan, Xing Hua , Xu, Lin , Schwartz, David A. , Han, Fang , Albagha, Omar , Ralston, Stuart H. , Sasaki, Tsukasa, Hibberd, Martin Lloyd , Xie, Gang , Försti, Asta , Landi, Stefano , Ellinghaus, David , Kim, Jong‐Won , Chang, Kai‐Ping , Martin, Nicholas G. , Gordon, Scott D. , Kimura, Masayuki , Hwang, Shih‐Jen , Manichaikul, Ani , Barr, R. Graham, Jonas, Jost B , Lin, Kuang , Amundadottir, Laufey , Kiemeney, Lambertus A , Eeles, Rosalind A , van Heel, David A , Gunter, Marc J , Canzian, Federico , Hung, Rayjean J , O'Mara, Tracy A , Abnet, Christian C , Haycock, Philip , Tumino, Rosario , Han, Jiali , Martin, Richard M , Severi, Gianluca , Reis, André , Zheng, Wei , Rotter, Jerome I , Carreras-Torres, Robert , Law, Matthew H , Davey Smith, George , Johansson, Mattias , Iles, Mark M , Morrison, Alanna C , Rice, Ken , Freedman, Neal D , Foo, Jia Nee , Levy, Daniel , Rice, Kenneth , Sapkota, Yadav , Wong, Tien Y , Liu, Jing

Mayo Clinic

JAMA Oncology | February 27, 2017 | Volume: 3 | Issue: 5 | Pages: 636

10.1001/jamaoncol.2016.5945 | PMID 28241208 Get It

Screen detection of serrated polyps by stool DNA multi-target testing (sDNA-MT): Comparison against fecal immunochemical occult blood testing (FIT).
Heigh, Russell I., Yab, Tracy C. , Simonson, Julie A., Boardman, Lisa A., Domanico, Michael J. , Lidgard, Graham P. , Ahlquist, David A. , Mahoney, Douglas W. , Boardman, Lisa A., Berger, Barry M.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 31 | Issue: 4_suppl | Pages: 341-341

10.1200/jco.2013.31.4_suppl.341 Get It

341 Background: Precursors to 1/3 of colorectal cancer (CRC), serrated polyps have historically been underdetected by screening due to their inconspicuous, nonhemorrhagic, and proximal nature. New generation sDNA-MT show high sensitivity for both CRC and advanced adenomas (Gastroenterology 2012;142:248), but screen detection of serrated polyps by this approach requires further validation. Aim: To assess and compare noninvasive detection of sessile serrated polyps >1cm (SSP) by sDNA-MT and a commercial quantitative FIT. Methods: In a blinded prospective study, a single stool sample used for both tests was collected from 456 asymptomatic adults prior to screening or surveillance colonoscopy (criterion standard). All 29 patients with SSP were included as cases and all 232 with no neoplastic findings as controls. Buffered stool samples were processed and frozen on receipt; Exact Sciences performed sDNA-MT in batches using optimized analytical methods (Gastroenterology 2012;142:S770). The sDNA-MT panel targets methylated BMP3 (mBMP3) and NDRG4, mutant KRAS, β-actin, and hemoglobin. FIT (Polymedco OC-FIT Check) was performed in separate lab <2 days post defecation and evaluated at cutoffs of 50 (FIT-50) and 100 ng/ml (FIT-100). Results: Age/sex distributions were similar in cases and controls: 40% vs 45% > 65 years and 51% vs 59% women, p=NS respectively. SSP median size was 1.2cm (range 1-3cm), 93% were proximal, and 64% had synchronous diminutive polyps. Among sDNA-MT markers, mBMP3 proved highly discriminant for SSP detection (AUC=0.87, p<0.00001); other DNA markers were less informative and provided no incremental sensitivity. Hemoglobin alone showed no discrimination (AUC=0.50, p=NS). At matched specificities, SSP detection by stool mBMP3 was significantly greater than by either FIT-50 or FIT-100 (Table). Conclusions: From a screening and surveillance setting, SSP can be detected noninvasively by stool assay of exfoliated DNA markers, especially mBMP3. FIT appears to have no value in SSP detection. [Table: see text]
Association of topoisomerase II expression and cancer-specific death in patients with surgically resected clear cell renal cell carcinoma.
Gardner, F., Serie, Daniel, Hilton, Tracy, Parasramka, Mansi, Eckel‐Passow, Jeanette E. , Cheville, John C. , Leibovich, Bradley C. , Parker, Alexander S. , Joseph, Richard W.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 31 | Issue: 6_suppl | Pages: 446-446

10.1200/jco.2013.31.6_suppl.446 Get It

446 Background: Despite the development of prognostic algorithms based on clinico-pathologic features, the ability to identify aggressive forms of clear cell renal cell carcinoma (ccRCC) remains suboptimal. Topoisomerase IIA (TOP2a) is a biomarker of DNA replication and a target for antineoplastic agents. Herein, we evaluate the association of TOP2a expression in ccRCC tumors with pathologic features of aggressiveness and risk of cancer-specific death. Methods: We identified 947 patients who underwent nephrectomy to treat clinically localized ccRCC between January 16, 1990, and September 27, 2006. TOP2a expression was assessed using IHC and scored as number of positive cells per mm2. We evaluated TOP2a expression using a continuous variable and tertile categories. For associations with pathologic features, we employed Kruskal-Wallis tests and for associations with cancer-specific survival, we generated Cox proportional hazard regression models. Results: HigherTOP2a expression is associated with later stage, higher grade and higher Mayo SSIGN score (all p < 0.001). The risk of death from RCC increases with increasing TOP2a expression (p trend < 0.0001). Compared to patients in the lowest tertile, those patients with tumors in the highest tertile of TOP2a expression were at increased risk of RCC death (HR=2.31 95% CI 1.64-3.25; p < 0.0001). Interestingly, among those patients with low risk disease (SSIGN score 0-3; ~95% 10 year survival), those with high TOP2a were at increased risk of RCC death (HR=3.09 95% CI 1.29-7.40; p = 0.01). Conclusions: Higher TOP2a expression is associated with more aggressive pathologic features and increased risk of cancer-specific death among patients undergoing surgery for localized ccRCC. If confirmed, these data support further inquiry for TOP2a as a prognostic and predictive biomarker for ccRCC patients.
Soluble ST2 in Heart Failure With Preserved Ejection Fraction
AbouEzzeddine, Omar F. , Stevens, Susanna R., Felker, G. Michael , Borlaug, Barry A. , Chen, Horng H. , Redfield, Margaret M. , McKie, Paul M. , Dunlay, Shannon M. , Tracy, Russell P. , Braunwald, Eugene , Borlaug, Barry A , AbouEzzeddine, Omar F

Mayo Clinic

Journal of the American Heart Association | February 19, 2017 | Volume: 6 | Issue: 2 | Pages: No page available

10.1161/jaha.116.004382 | PMID 28214792 Get It

Background Soluble ST2 is a biomarker that is elevated in certain systemic inflammatory diseases. Comorbidity‐driven microvascular inflammation is postulated to play a key role in heart failure with preserved ejection fraction ( HF p EF ) pathophysiology, but data on how sST 2 relates to clinical characteristics or inflammatory conditions or biomarkers in HF p EF are limited. We sought to determine circulating levels and clinical correlates of sST 2 in HF pEF. Methods and Results At enrollment, patients (n=174) from the Phosphodiesterase‐5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) trial of sildenafil in HF p EF had sST 2 levels measured. Clinical characteristics; cardiac structure and function; exercise performance; and biomarkers of neurohumoral activation, systemic inflammation and fibrosis, and myocardial necrosis were assessed in relation to sST 2 levels. Median sST 2 levels in male and female HFpEF patients were 36.7 ng/mL (range 30.9–49.2 ng/mL; reference range 4–31 ng/mL) and 30.8 ng/mL (range 25.3–39.3 ng/mL; reference range 2–21 ng/mL), respectively. Among HF p EF patients, higher sST 2 levels were associated with the presence of diabetes mellitus; atrial fibrillation; renal dysfunction; right ventricular pressure overload and dysfunction; systemic congestion; exercise intolerance; and biomarkers of systemic inflammation and fibrosis, neurohumoral activation, and myocardial necrosis ( P <0.05 for all). sST 2 was not associated with left ventricular structure or left ventricular systolic or diastolic function. Conclusions In HF p EF , sST 2 levels were associated with proinflammatory comorbidities, right ventricular pressure overload and dysfunction, and systemic congestion but not with left ventricular geometry or function. These data suggest that sST2 may be a marker of systemic inflammation in HF p EF and potentially of extracardiac origin. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00763867.
Subacute demyelinating polyradiculoneuropathy complicating Epstein–Barr virus infection in GATA2 haploinsufficiency
Kazamel, Mohamed , Klein, Christopher J. , Benarroch, Eduardo E. , Patnaik, Mrinal M. , Tracy, Jennifer A., Klein, Christopher J

Mayo Clinic

Muscle & Nerve | January 17, 2017 | Volume: 57 | Issue: 1 | Pages: 150-156

10.1002/mus.25581 | PMID 28093780 Get It

ABSTRACTIntroduction: Autosomal dominant haploinsufficiency of GATA2 causes monocytopenia and natural killer cell lymphopenia, resulting in predisposition to mycobacterial, fungal, and viral infections. Methods: Herein we report on the clinical, serologic, electrophysiologic, and pathologic evaluations of a 29‐year‐old woman with GATA2 haploinsufficiency and active Epstein–Barr virus (EBV) infection complicated by subacute painful neuropathy. Results: Nerve conduction and electromyography studies showed predominantly demyelinating sensorimotor polyradiculoneuropathy. Lumbar spine MRI showed thickening and enhancement of the cauda equina nerve roots. Serum and cerebrospinal fluid anti‐IgG and IgM EBV capsid and nucleic acid antibodies were positive. Sural nerve biopsy showed microvasculitis and an increased frequency of fibers with segmental demyelination. Intravenous immunoglobulin and steroids improved the patient's neuropathy. Conclusion: GATA2 mutation–related immunodeficiency may predispose to EBV‐associated subacute demyelinating polyradiculoneuropathy by both viral susceptibility and immune dysregulation. In patients who present in this manner, immunodeficiency syndromes should be considered when lymphomatous infiltration is excluded. Immunotherapy can be helpful. Muscle Nerve 57: 150–156, 2018
GAD65 neurological autoimmunity
McKeon, Andrew , Tracy, Jennifer A., McKeon, Andrew

Mayo Clinic

Muscle & Nerve | January 7, 2017 | Volume: 56 | Issue: 1 | Pages: 15-27

10.1002/mus.25565 | PMID 28063151 Get It

ABSTRACT The glutamic acid decarboxylase 65‐kilodalton isoform (GAD65) antibody is a biomarker of autoimmune central nervous system (CNS) disorders and, more commonly, nonneurological autoimmune diseases. Type 1 diabetes, autoimmune thyroid disease, and pernicious anemia are the most frequent GAD65 autoimmune associations. One or more of these disorders coexists in approximately 70% of patients with GAD65 neurological autoimmunity. Neurological phenotypes have CNS localization and include limbic encephalitis, epilepsy, cerebellar ataxia, and stiff‐person syndrome (SPS), among others. Classic SPS is a disorder on the spectrum of CNS hyperexcitability which also includes phenotypes that are either more restricted (stiff‐limb syndrome) or more widespread (progressive encephalomyelitis with rigidity and myoclonus). GAD65 antibody is not highly predictive of a paraneoplastic cause for neurological disorders, but diverse cancer types have been occasionally reported. For all phenotypes, responses to immunotherapy are variable (approximately 50% improve). GAD65 autoimmunity is important to recognize for both coexisting nonneurological autoimmune associations and potential immunotherapy‐response. Muscle Nerve 56 : 15–27, 2017
Outcomes of Holmium Laser Enucleation of the Prostate in the Re-Treatment Setting
Marien, Tracy , Kadıhasanoğlu, Mustafa , Tangpaitoon, Teerayut , York, Nadya , Blackburne, Andrew T. , Abdul-Muhsin, Haidar , Borofsky, Michael S. , Krambeck, Amy E. , Humphreys, Mitchell R. , Lingeman, James E., Miller, Nicole L. , Miller, Nicole L

Mayo Clinic

Journal of Urology | December 30, 2016 | Volume: 197 | Issue: 6 | Pages: 1517-1522

10.1016/j.juro.2016.12.098 | PMID 28043843 Get It

Introducing Essential Oils into Pediatric and Other Practices at an Academic Medical Center
Conlon, Patricia M. , Haack, Kristen M., Rodgers, Nancy J., Dion, Liza J., Cambern, Kari L., Rohlik, Gina, Nelson, Dawn E., Barry, Tracy A., Ayres, Sara , Cutshall, Susanne M. , Rohlik, Gina M, Ayres, Sara J

Mayo Clinic

Journal of Holistic Nursing | November 11, 2016 | Volume: 35 | Issue: 4 | Pages: 389-396

10.1177/0898010116677400 | PMID 27837082 Get It

Aromatherapy is an integrative intervention that uses essential oils to address symptom management, potentially as a first-line intervention or as a complement to other medical treatments. Aromatherapy is gaining widespread acceptance and increased scientific evidence of efficacy. Integrative and holistic nursing care uses integrative therapies such as aromatherapy and the principle of moving from a less invasive intervention to a more invasive intervention according to patient needs, symptoms, and preferences. Aromatherapy is often provided as a minimally invasive, independent, and integrative nursing intervention. This article describes the process used to introduce essential oils into practices at a large Midwestern academic medical center.